The Latest Breaking News from Eli Lilly

The S&P 500's plunge in August caught most investors off guard. It's quite a win if you scooped up the handful of gainers in the tough month.

Alzheimer research made a breakthrough last month when Eli Lilly's drug donanemab slowed cognitive decline in 47% of those taking it. It follows two other drugs, lecanemab and aducanumab, that target amyloid protein buildup in the brain. However, these drugs can cause fatal brain bleeding and seizures. Oxidative stress hypothesis…

Before joining Tesla in July, Michael Hildebrand was executive director of projects at Eli Lilly, where he spent the previous 19 years of his career.

The market rally faces a key test. Nvidia is holding strong, but some Magnificent 7 stocks are ailing. Two AI plays dived late.

The main benchmarks fell Tuesday, but healthcare stocks outperformed as Eli Lilly and Novo Nordisk surged.

Eli Lilly’s diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected

Eli Lilly stock broke out bullishly Tuesday after the drugmaker walloped forecasts partly due to diabetes treatment powerhouse Mounjaro.

The Dow Jones Industrial Average dived 450 points Tuesday on Moody's bank downgrades. Hot AI stock Palantir Technologies dived on second-quarter earnings results.

Drugmaker Novo Nordisk focuses on Black lawmakers and opinion leaders to spread the message that obesity is a chronic disease — worth treating at a cost of $1,000 or more a month.